Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

p53/p16-Independent Epigenetic Therapy With Oral Decitabine/Tetrahydrouridine for Advanced Pancreatic Cancer That Has Progressed Through One or More Lines of Therapy

NCT02847000 is registered in ClinicalTrials.gov with Yogen Saunthararajah as lead sponsor.

NCT NCT02847000
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02847000 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
p53/p16-Independent Epigenetic Therapy With Oral Decitabine/Tetrahydrouridine for Advanced Pancreatic Cancer That Has Progressed Through One or More Lines of Therapy
Lead sponsor
Yogen Saunthararajah
Phase
Phase 1
Overall status
Completed
Start date
December 20, 2016
Completion date
October 30, 2017
Enrollment
13 (actual)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

metastatic pancreatic adenocarcinoma